-
EP2446887
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP2446887
| EP2446887 - Use of danazol for the treatment of Alzheimer's disease [Right-click to bookmark this link] | Status | The application is deemed to be withdrawn Status updated on 17.02.2017 Database last updated on 18.11.2024 | |
| Former | Examination is in progress Status updated on 13.11.2016 | Most recent event Tooltip | 17.02.2017 | Application deemed to be withdrawn | published on 22.03.2017 [2017/12] | Applicant(s) | For all designated states Ampio Pharmaceuticals, Inc. 373 Inverness Parkway Suite 200 Englewood, CO 80112 / US | [2015/24] |
| Former [2013/52] | For all designated states Ampio Pharmaceuticals, Inc. 5445 DTC Parkway Suite 925 Greenwood Village, CO 80111 / US | ||
| Former [2012/18] | For all designated states DMI Biosciences, Inc. 3601 S. Clarkson Street Suite 420 Englewood, CO 80110-3948 / US | Inventor(s) | 01 /
Bar-Or, David 900 E. Oxford Lane Englewood, Colorado 80110 / US | [2012/18] | Representative(s) | Hoefer & Partner Patentanwälte mbB Pilgersheimer Straße 20 81543 München / DE | [N/P] |
| Former [2012/18] | Schaeberle, Steffen Hoefer & Partner Patentanwälte Pilgersheimer Strasse 20 81543 München / DE | Application number, filing date | 11010269.6 | 12.07.2006 | [2012/18] | Priority number, date | US20050698723P | 12.07.2005 Original published format: US 698723 P | US20050711157P | 24.08.2005 Original published format: US 711157 P | US20050711158P | 24.08.2005 Original published format: US 711158 P | [2012/32] |
| Former [2012/18] | US200569872305P | 12.07.2005 | |
| US200571115705P | 24.08.2005 | ||
| US200571115805P | 24.08.2005 | Filing language | EN | Procedural language | EN | Publication | Type: | A2 Application without search report | No.: | EP2446887 | Date: | 02.05.2012 | Language: | EN | [2012/18] | Type: | A3 Search report | No.: | EP2446887 | Date: | 15.08.2012 | Language: | EN | [2012/33] | Search report(s) | (Supplementary) European search report - dispatched on: | EP | 13.07.2012 | Classification | IPC: | A61K31/569 | [2012/18] | CPC: |
A61L27/54 (EP,US);
A61K31/56 (EP,US);
A61K31/58 (EP,US);
A61P19/02 (EP);
A61P19/04 (EP);
A61P21/00 (EP);
A61P25/00 (EP);
A61P25/14 (EP);
A61P25/16 (EP);
A61P25/28 (EP);
A61P27/00 (EP);
A61P27/02 (EP);
A61P27/06 (EP);
A61P29/00 (EP);
A61P35/00 (EP);
A61P35/04 (EP);
A61P37/08 (EP);
A61P9/00 (EP);
| Designated contracting states | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR [2012/18] | Extension states | AL | Not yet paid | BA | Not yet paid | HR | Not yet paid | MK | Not yet paid | RS | Not yet paid | Title | German: | Verwendung von Danazol zur Behandlung von Morbus Alzheimer | [2012/18] | English: | Use of danazol for the treatment of Alzheimer's disease | [2012/18] | French: | Utilisation du danazol pour le traitement de la maladie de Alzheimer | [2012/18] | Examination procedure | 15.02.2013 | Amendment by applicant (claims and/or description) | 15.02.2013 | Examination requested [2013/13] | 19.03.2013 | Despatch of a communication from the examining division (Time limit: M06) | 27.09.2013 | Reply to a communication from the examining division | 06.06.2016 | Despatch of a communication from the examining division (Time limit: M04) | 18.10.2016 | Application deemed to be withdrawn, date of legal effect [2017/12] | 14.11.2016 | Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time [2017/12] | Parent application(s) Tooltip | EP06787393.5 / EP1919290 | Divisional application(s) | The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued (EP20060787393) is 22.12.2009 | Fees paid | Renewal fee | 29.12.2011 | Renewal fee patent year 03 | 29.12.2011 | Renewal fee patent year 04 | 29.12.2011 | Renewal fee patent year 05 | 29.12.2011 | Renewal fee patent year 06 | 25.07.2012 | Renewal fee patent year 07 | 10.07.2013 | Renewal fee patent year 08 | 14.07.2014 | Renewal fee patent year 09 | 10.07.2015 | Renewal fee patent year 10 | Penalty fee | Additional fee for renewal fee | 31.07.2016 | 11 M06 Not yet paid |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [XI]WO0104349 (PASTEUR INSTITUT [FR], et al) [X] 1,2 * page 6, lines 17-19 * * claims 10,11 * [I] 1,2; | [XI]US6333317 (LEE ROBERT K K [US], et al) [X] 1,2 * claims 1-13 * [I] 1,2; | [I] - WOOD P L, "Microglia: A possible cellular target for pharmacological approaches to neurodegenerative disorders", DRUG NEWS AND PERSPECTIVES 1994 ES, (1994), vol. 7, no. 3, ISSN 0214-0934, pages 138 - 157, XP001526033 [I] 1,2 * page 141, column r, paragraph 1 * * page 142, column m, paragraph 3 * | by applicant | US3135743 | US3296255 | US3296295 | GB1123770 | GB2130588 | US5407926 | US6060463 | GB2345851 | WO0130337 | WO0168053 | WO02080930 | WO2004043480 | WO2004058289 | US2005101582 | - BUCKNALL, RHEUMATOLOGY, (2005), vol. 44, no. 10, pages 1207 - 1209 |